![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, May 21, 2023 2:11:26 PM
Holding Holder Report Quarter Stock Shares Held Value Portfolio % Shares Vs.
Prev Report Holding History
1 Marker Therapeutics, Inc.
MRKR NEA Management Company LLC 2023Q1 Stock 1,071,428 $760,714 0.0526% 1,071,428
(New Position) Histor
2 Deleted
3 Marker Therapeutics, Inc.
MRKR VANGUARD GROUP INC 2023Q1 Stock 166,881 $118,486 0.0000% 166,881
(New Position) History
4 Marker Therapeutics, Inc.
MRKR Long Focus Capital Management LLC 2023Q1 Stock 146,100 $103,731 0.0059% 146,100
(New Position) History
5 Marker Therapeutics, Inc.
MRKR GEODE CAPITAL MANAGEMENT LLC 2023Q1 Stock 57,751 $41,003 0.0000% 57,751
(New Position) History
6 Marker Therapeutics, Inc.
MRKR AR ASSET MANAGEMENT INC 2023Q1 Stock 40,700 $29,000 0.0078% 40,700
(New Position) History
7 Marker Therapeutics, Inc.
MRKR MILLENNIUM MANAGEMENT LLC 2023Q1 Stock 30,778 $22,000 0.0000% 30,778
(New Position) History
8 Marker Therapeutics, Inc.
MRKR MATRIX ASSET ADVISORS INC 2023Q1 Stock 25,000 $17,750 0.0026% 25,000
(New Position) History
9 Marker Therapeutics, Inc.
MRKR RENAISSANCE TECHNOLOGIES LLC 2023Q1 Stock 19,350 $14,000 0.0000% 19,350
(New Position) History
10 Marker Therapeutics, Inc.
MRKR STATE STREET CORP
STT 2023Q1 Stock 18,748 $13,311 0.0000% 18,748
(New Position)
# Holding Holder Report Quarter Stock Shares Held Value Portfolio % Shares Vs.
Prev Report Holding History
11 Marker Therapeutics, Inc.
MRKR SUSQUEHANNA INTERNATIONAL GROUP LLP 2023Q1 Stock 17,606 $12,500 0.0000% 17,606
(New Position) History
12 Marker Therapeutics, Inc.
MRKR Creative Planning 2023Q1 Stock 17,562 $12,469 0.0000% 17,562
(New Position) History
13 Marker Therapeutics, Inc.
MRKR WEDBUSH SECURITIES INC 2023Q1 Stock 12,005 $9,000 0.0005% 12,005
(New Position) History
14 Marker Therapeutics, Inc.
MRKR NORTHERN TRUST CORP
NTRS 2023Q1 Stock 10,881 $7,726 0.0000% 10,881
(New Position) History
15 Marker Therapeutics, Inc.
MRKR ADVISOR GROUP HOLDINGS INC. 2023Q1 Stock 7,465 $5,298 0.0000% 7,465
(New Position) History
16 Marker Therapeutics, Inc.
MRKR UBS Group AG 2023Q1 Stock 5,609 $3,982 0.0000% 5,609
(New Position) History
17 Marker Therapeutics, Inc.
MRKR BANK OF AMERICA CORP
BAC 2023Q1 Stock 4,669 $3,315 0.0000% 4,669
(New Position) History
18 Marker Therapeutics, Inc.
MRKR Tower Research Capital LLC (TRC) 2023Q1 Stock 4,248 $3,000 0.0001% 4,248
(New Position) History
19 Marker Therapeutics, Inc.
MRKR Riggs Asset Managment Co. Inc. 2023Q1 Stock 2,550 $1,811 0.0007% 2,550
(New Position) History
20 Marker Therapeutics, Inc.
MRKR MORGAN STANLEY
MS 2023Q1 Stock 1,940 $1,377 0.0000% 1,940
(New Position) Histor
![Bullish](/static/images/ih2-bull.png)
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM